Solvay Pharma: Dealing Its Way Into the Limelight

BMS and Wyeth are two of the latest to have noticed Solvay’s unusually healthy pipeline. The mid-sized group’s new dealmaking drive means they’re unlikely to be the last.

By Melanie Senior

It's hardly surprising that much of the biopharma industry hasn't even heard of Belgium's Solvay SA . For one,...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo